rap chart, page-621

I hold LBT and RAP, yes the 220% rise was fun, but LBT was bound to drop, simply due to actual sales. It's product is a fully automated pathology screening unit that is quicker and more efficient than current system of analysing specimens, recent approval was for MRSA module. The problem is that they have only sold one unit. Great product, time will tell if this little Aussie co. can sell its expensive machines to the big players.

RAP is different, no manufacturing costs, no expensive machinery. If they are accepted as a scientifically accepted screening tool, revenue could occur very quickly, with a massive market potential.

Hope our patience will be rewarded soon, thanks for thr great info posted...makes the wait easier!